News: Admedus revenue up 7.09% for FY2014, page-19

why don't you spell it out Ralom - or is your comment just wishful thinking?

now I fully realise that stock prices move ahead of profitability (I've only been a market observer for nearly 30 years) so normally, I might agree with you - there is usually scope for sp improvement prior to profitability. But AHZ has another problem doesn't it?

the problem, as I see it, is AHZ's massive share register. Some no doubt think that an sp of 50c/$1 is somewhere close at hand (or at least in the near future) but stop and think how many patches you need to flog to cover a company with 1.6 billion shares fully diluted at those prices.

maybe the vaccine program can pull the chook out of the fire? - but Phase II trial results have to be 2/3 years away? and at this stage there is no certainty of success - (read AHZ's FY report before posting something stupid about Phase II results).

so for me, AHZ has a long hard grind in front of it. It's screwed on several fronts IMO in terms of any quick outcomes for sp rises. AHZ might have a great product and some expectation of a success at Ph II trials but it's gonna be hard watching it move slower than a tortoise....

I'm not telling anyone what to do here, just explaining my POV. I know what I'm gonna do.